CLINICAL TRIALS PROFILE FOR AGGRASTAT
✉ Email this page to a colleague
All Clinical Trials for aggrastat
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00251576 ↗ | Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 1999-11-01 | A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner. Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack. |
| NCT00300833 ↗ | Treating Acute MI Patients With Aggrastat on Their Way to Hospital | Unknown status | The Baruch Padeh Medical Center, Poriya | Phase 4 | 2006-01-01 | Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital. |
| NCT00383136 ↗ | FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab | Completed | University of Bologna | Phase 4 | 2003-06-01 | The elective("standard of care") treatment of ST - elevation acute myocardial infarction (STEMI) currently consists of primary angioplasty with stent implantation during administration of Abciximab, a inhibitor of GP IIb/IIIa platelet receptor. Tirofiban is another potent inhibitor of GP IIb/IIIa platelet receptor with an efficacy on platelet aggregation inhibition equal to or greater than Abciximab if a high dose bolus is used, i.e. 25 microg/kg, (platelet aggregation inhibition > 90% 15 minutes after infusion). It can therefore be hypothesized that this drug can improve the results of primary angioplasty to the same extent as Abciximab. The aim of this study is to compare the efficacy, in terms of myocardial reperfusion indices, of Abciximab and high dose of Tirofiban in primary angioplasty for STEMI, both in the case of treatment before transfer and of treatment in the catheterization laboratory during the procedure. The reference hypothesis for the study objective is the equivalence or the non-inferiority of Tirofiban with respect to Abciximab. |
| NCT00566891 ↗ | Safety of High-dose Tirofiban During Coronary Angioplasty | Completed | S. Anna Hospital | Phase 4 | 2007-12-01 | This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for aggrastat
Condition Name
Clinical Trial Locations for aggrastat
Trials by Country
Clinical Trial Progress for aggrastat
Clinical Trial Phase
Clinical Trial Sponsors for aggrastat
Sponsor Name
